Download MendeleyA catalase inhibitor: Targeting the NADPH-binding site for castration-resistant prostate cancer therapy.
Cao, Y.Y., Chen, Y.Y., Wang, M.S., Tong, J.J., Xu, M., Zhao, C., Lin, H.Y., Mei, L.C., Dong, J., Zhang, W.L., Qin, Y.X., Huang, W., Zhang, D., Yang, G.F.(2023) Redox Biol 63: 102751-102751
- PubMed: 37216701 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1016/j.redox.2023.102751
- Primary Citation Related Structures:
8HID - PubMed Abstract:
Catalase (CAT) is an important antioxidant enzyme that breaks down H 2 O 2 into water and oxygen. Inhibitor-modulating CAT activity in cancer cells is emerging as a potential anticancer strategy. However, the discovery of CAT inhibitors towards the heme active center located at the bottom of long and narrow channel has made little progress. Therefore, targeting new binding site is of great importance for the development of efficient CAT inhibitors. Here, the first NADPH-binding site inhibitor of CAT, BT-Br, was designed and synthesized successfully. The cocrystal structure of BT-Br-bound CAT complex was determined with a resolution of 2.2 Å (PDB ID:8HID), which showed clearly that BT-Br bound at the NADPH-binding site. Furthermore, BT-Br was demonstrated to induce ferroptosis in castration-resistant prostate cancer (CRPC) DU145 cells and eventually reduce CRPC tumors in vivo effectively. The work indicates that CAT has potential as a novel target for CRPC therapy based on ferroptosis inducing.
- National Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensor Technology and Health, Central China Normal University, Wuhan, 430079, PR China.
Organizational Affiliation:
